Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation
NCT04235140
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
52
Enrollment
INDUSTRY
Sponsor class
Conditions
Cystic Fibrosis
Interventions
DRUG:
LUM/IVA
Sponsor
Vertex Pharmaceuticals Incorporated